NCT05950061 is a Phase 3 clinical trial of Sertraline in Major Depressive Disorder, sponsored by KRL Hospital, Islamabad.

Who is sponsoring NCT05950061?

NCT05950061 is sponsored by KRL Hospital, Islamabad.

What drugs are being tested in NCT05950061?

Interventions in NCT05950061: Sertraline, Escitalopram.

What condition does NCT05950061 study?

NCT05950061 studies Major Depressive Disorder.

Is NCT05950061 still recruiting?

NCT05950061 is currently completed. Last updated 18 July 2023.

Last reviewed 2023-07-18 · How we verify

NCT05950061

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder

Completed Phase 3 Last updated 18 July 2023

What this trial tests

Phase 3 trial testing Sertraline in Major Depressive Disorder in 744 participants. Completed in 26 February 2023.

Timeline

1 June 2022

Primary endpoint
29 October 2022

26 February 2023

Quick facts

Lead sponsor	KRL Hospital, Islamabad
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	744
Start date	1 June 2022
Primary completion	29 October 2022
Estimated completion	26 February 2023
Sites	1 location across Pakistan

Drugs / interventions tested

Sertraline (sertraline) — full drug profile →
Escitalopram (escitalopram) — full drug profile →

Conditions studied

Major Depressive Disorder — all drugs for Major Depressive Disorder →

Sponsor

KRL Hospital, Islamabad

Who can join

Adults 20 to 80, any sex, with Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective: The aim of this randomized controlled trial was to compare the efficacy and safety of sertraline and escitalopram in participants with moderate to severe major depressive disorder (MDD). Methods: A total of 744 participants with moderate to severe MDD were randomly assigned to receive either sertraline or escitalopram for 8 weeks. Drug dosages and titration schedules were based on the recommendations of the prescribing information for each product and according to the judgment of the clinicians involved in the study. The primary outcome measures were changes from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Clinical Global Impression (CGI) scale as well as frequency of adverse events in both groups.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sertraline

Trials testing the same drug.

NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression · Phase 2 · recruiting
NCT05603104 — Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First- · Phase 3 · recruiting
NCT06827431 — The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression · Phase 3 · not yet recruiting
NCT05973786 — The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in · Phase 3 · recruiting
NCT05892744 — Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression · Phase 4 · recruiting

Other recruiting trials for Major Depressive Disorder

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
NCT07316803 — Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness · NA · recruiting
NCT07242105 — Optimizing Brain Excitability in Depression · NA · recruiting

Other KRL Hospital, Islamabad trials

Trials by the same sponsor.

NCT05469529 — Bupivacaine Alone vs Bupivacaine and Dexmed in Cesarean Deliveries · NA · unknown
NCT05735106 — NC/TMD Ratio As a Difficult Airway Predictor in Obese Patients · completed
NCT05958277 — Vitamin B12 vs B3 for Nerve Regeneration and Functional Recovery After Pediatric Traumatic Brain Injury · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05950061 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by KRL Hospital, Islamabad
Last refreshed: 18 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05950061.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing